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Abstract
Introduction
Uncertainty about levels of employee use of an insur-
ance benefit for smoking-cessation treatment has present-
ed a barrier to employers considering the adoption of such
coverage. This study examined self-reported awareness
and use of a new insurance benefit for smoking-cessation
treatment among a sample of Wisconsin state employees,
retirees, and adult dependents.
Methods
We evaluated the self-reported use of insurance cover-
age for smoking-cessation treatment during the first 2
years of its availability to the Wisconsin state employee,
retiree, and adult dependent population. We conducted
analyses of responses to smoking-related questions in
2001 and 2002 cross-sectional surveys of insured state
employees, retirees, and adult dependents, weighted to
represent this population.
Results
In 2002, benefit use among smokers aware of the bene-
fit was 39.6%, and benefit use among smokers unaware of
the benefit was 3.5%. Only 27.4% of smokers were aware
of the benefit in 2002; use among all smokers was 13.6%.
Of all smokers, 30.4% used smoking-cessation treatment
medication (over-the-counter or covered) in 2002. Smoking
prevalence was 15.6% in 2001 and 13.2% in 2002.
Conclusion
In an educated employee population, self-reported smok-
ing-cessation treatment benefit use was modest among all
smokers during its first 2 years of availability. Benefit
awareness was low in this educated population, which
may help explain low use rates, particularly given the 30%
of all smokers who attempted to quit smoking with the
help of smoking-cessation treatment medication. These
data provide use-rate estimates for states contemplating
adoption of an evidence-based smoking-cessation treat-
ment benefit.
Introduction
As part of a comprehensive tobacco-control strategy,
public health experts recommend insurance coverage for
evidence-based smoking-cessation treatments (SCTs)
such as smoking-cessation medications approved by the
Food and Drug Administration (FDA) (1-3). These med-
ications can double or triple the likelihood of quitting
smoking compared with quitting without such treatment
(3). Moreover, insurance coverage for evidence-based
SCTs has been shown to reduce smoking rates in insured
populations (4,5). Although some health plans have
adopted these public health recommendations, a sizeable
gap remains between the recommended availability and
the actual availability of such coverage. For example, a
sample of U.S. health plans reported that 41% of their
best-selling commercial health maintenance organiza-
tion (HMO) products provide coverage for at least one
FDA-indicated smoking-cessation medication (6).
Coverage among employers varies despite research
showing that workplace productivity increases and
absenteeism decreases among former smokers compared
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with smokers (7). Nationally, 23% to 64% of employers
provide some form of insurance coverage for SCTs (8,9).
Health insurers and employers have offered various
explanations for the limited provision of health insurance
coverage for SCTs; among these is their uncertainty
about the levels of use of such coverage. 
In a series of focus groups, employers cited low benefit-
use rates as one of the primary reasons for not covering
preventive health services, including SCTs, and ques-
tioned the need to provide coverage for services that their
employees rarely used (10). Health care purchasers, insur-
ance brokers, and benefits consultants have named a lack
of beneficiary demand as one explanation for their limited
efforts to negotiate health-behavior change benefits and
programs, including SCTs (11). Insurers have also
expressed skepticism about member use of SCT coverage
and thus the need to cover it. Insurers have asserted that
many people quit smoking on their own (12), and that
smoking-cessation medication is available over-the-count-
er (OTC); thus, SCT coverage is redundant (13).
Uncertainty about levels of SCT use poses a second chal-
lenge to adopting such coverage: employers and insurers
find it difficult to anticipate the cost of SCT coverage. At a
minimum, employers require short-term cost estimates for
an SCT benefit to make a coverage decision (14).
Employers have further indicated that to increase cover-
age for preventive services such as SCTs, information on
coverage costs and potential returns on such an invest-
ment is also needed (10).
In recent years, several studies have addressed the
extent to which insured individuals use SCT benefits
when they are available. In evaluating four SCT-benefit
designs on benefit use and smoking outcomes, Curry et al
estimated SCT benefit-use rates of 2.4% to 10% among
smokers; rates depended upon the benefit design (4). To
use the medication component of these benefits, the
health plan required smokers to participate in a smoking-
cessation counseling program. This requirement may
have reduced use of the benefit. If so, the study findings
may underestimate population use rates for a pharma-
cotherapeutic benefit that does not require participation
in a counseling program.
In another study, Schauffler et al examined the rela-
tionship between SCT coverage, SCT use, and smoking
outcomes; they reported that 25% of smokers with SCT
coverage used the covered medication (5). The sample
included only smokers who were willing to participate in
a randomized controlled trial. To the extent that the
smokers in the sample were more interested in quitting
than a population-based sample of smokers (they volun-
teered for the study), the results may overestimate SCT
benefit-use rates.
In other aspects of the studies discussed above,
Schauffler et al and Curry et al showed that providing
insurance coverage for SCTs increases treatment use (5)
and reduces smoking prevalence within defined popula-
tions (4). In contrast, Boyle et al found similar SCT-use
rates for smokers with and without SCT insurance cover-
age; approximately 24% of smokers used bupropion, and
27% used nicotine replacement therapy to make an
attempt to quit (15). In the Boyle sample, almost half of
smokers reported an interest in quitting within the next
30 days. Because of the interest in quitting among smok-
ers in the sample, the treatment-use rates observed in this
population may overestimate rates that an employer or
insurer could expect from their total population. For exam-
ple, in a population-based study, Wewers et al found that
approximately 8% of daily smokers planned to make an
attempt to quit during the next 30 days. However, this
same group of smokers also reported that they had
stopped smoking for a day or more during the past 12
months (16). One cannot conclude that the results of these
three studies on SCT benefit use will apply to population-
based studies.
The purpose of the present population-based study is to
evaluate the self-reported use of insurance coverage for
SCTs during the first 2 years of its availability to the
Wisconsin state employee, retiree, and adult dependent
population. The study findings are intended to reduce the
uncertainty surrounding what employers, particularly
large public employers, can expect when they provide a
new SCT benefit.
In January 2001, the Wisconsin Department of
Employee Trust Funds (DETF) introduced a health insur-
ance benefit for SCTs for its approximately 183,000
insured employees and their dependents. The DETF
required that state employee health insurance plans pro-
vide counseling and prescription medication for smoking
cessation. (One health plan was exempt from this require-
ment. Its members, approximately 10% of the total
insured population, were excluded from this study.) The
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pharmacotherapy and one office visit for counseling per
calendar year. Counseling was not required to obtain
pharmacotherapy, and OTC medication was not covered
by the benefit. There was no lifetime limit. Table 1 
provides a summary of the benefit.
Before January 2001, the availability and scope of cov-
erage for SCTs for Wisconsin state employees, retirees,
and adult dependents varied widely. A 1998 survey found
that 7 of the 25 Wisconsin state employer-sponsored
health plans covered some form of SCT. Significant up-
front patient cost sharing was often required, with reim-
bursement contingent upon the completion of counseling,
maintaining abstinence from smoking, or both (13). Thus,
the benefit introduced in 2001 expanded the availability of
SCTs for the insured state employee, retiree, and adult
dependent population.
The DETF notified its employee and retiree populations
in October 2000 of the new SCT benefit in the open enroll-
ment materials provided to employees, retirees, and adult
dependents. A summary of the SCT benefit was included
among other health plan or benefit changes listed in the
first two pages of the group health insurance plans and
provisions booklet (17).
Methods
From approximately March through June in both 2001
and 2002, the DETF conducted a computer-assisted tele-
phone-interviewing (CATI) survey of covered state
employees, retirees, and adult dependents to assess their
experiences and satisfaction with their health insurance
plan and health care. The DETF used the adult commer-
cial Consumer Assessment of Health Plans Survey
(CAHPS) (18), adding questions on smoking to the CAHPS
core instrument for survey years 2001 and 2002. Added
questions covered current smoking status, awareness of
the SCT insurance benefit, use of the SCT benefit, and in
2002, use of over-the-counter SCTs. We collected sociode-
mographic data on age, education, and sex.
CATI interviewers progressed through a four-step 
training process, including 1) learning about the 
data-collection instrument, 2) mock interviewing, 3) moni-
toring veteran interviewers, and 4) ongoing performance
feedback through the data-collection period. A minimum 
of 10% of all interviews was monitored by telephone 
laboratory supervisors.
The sampling frame included all state employee 
and retiree contracts for individual or family employer-
sponsored health insurance in which employees had been
in their selected health plan for 12 or more months. In
2001, the sampling frame included 82,984 contracts; in
2002, the sampling frame included 69,600 contracts. The
sampling frame was stratified by health insurance plan or
carrier (henceforth called plan), with 19 plans in 2001 and
22 plans in 2002. The sample size in each stratum was
based on two considerations: 1) the estimated number of
state employees, retirees, and dependents in each plan and
2) the state’s interest in reaching a precision level of ±5%
of each plan’s population mean for the response to each
survey question with 95% confidence. After the sample
size by stratum was determined, a random sample of
employee and retiree health insurance contracts was
selected within each stratum with a goal of achieving a
70% response rate for each stratum. Each contract in each
stratum had a known, nonzero probability of selection.
Table 2 presents the number of contracts, the estimated
number of state employees, retirees, and adult dependents
and the number of respondents for each stratum.
The survey respondent was the person in the household
most knowledgeable about the health care received by all
family members covered by the employer-sponsored health
plan. These respondents constituted our sample. The
interviewer used the following screening question to iden-
tify this respondent: “For this study, we are interested in
speaking to the person who knows the most about the
health care received by all of the people in your family cov-
ered by your health care plan. Would that be you?” If the
respondent indicated that he or she was that person, the
interview continued. If not, the interviewer asked the
respondent to identify the appropriate person. If neces-
sary, the interviewer arranged a call back to contact this
person. The interviewer then began the interview with the
above screening question.
The survey contact rates (the number of households con-
tacted divided by the total sample) were 64% for 2001 and
70% for 2002. The survey refusal rates (the number of
households that refused to participate divided by the total
sample) were 14% for 2001 and 12% for 2002. The survey
response rate in both years was 64%. We calculated the
response rate using the Council of American Survey
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Research Organizations method employed for the
Behavioral Risk Factor Surveillance System (19).
According to this method, the numerator is the number of
completed interviews, and the denominator includes all
valid households in the sampling frame (i.e., living
employees, retirees, and adult dependents, working tele-
phone number, valid health plan membership). This
method allocates households with unknown validity (e.g.,
busy phone line, no answer) to valid or invalid status
according to the proportion of valid and invalid households
among those with known validity. The final sample includ-
ed 5609 individuals in 2001 and 6518 individuals in 2002
who subscribed to health plans that were required to pro-
vide coverage for SCT.
Assessing smoking status
There were some differences in the smoking-related
questions in the 2001 survey compared with the survey
questions in 2002 because the 2001 survey was conducted
within a few months of the introduction of the new SCT
benefit. In 2001, we included a question to assess smoking
status just before the introduction of the benefit.
Respondents were asked if they had smoked every day,
some days, or not at all during the month of December
2000. This question was used only to estimate the number
of individuals who might use insurance coverage for SCT
in 2001. 
In 2001 and 2002, we asked respondents if they had
smoked every day, some days, or not at all during the past
12 months. Individuals were considered smokers if they
reported smoking every day or some days. Responses to
this question were used to estimate the smoking preva-
lence rate for the state employee population, to compare
estimates between the 2 years, and to estimate the popu-
lation eligible to use the SCT benefit in 2002.
Measuring awareness of SCT insurance benefits
We also asked respondents if prescription medications
for smoking cessation were covered by their health insur-
ance plan. The question included the list of medications
that were actually covered by the DETF’s health insurance
benefits package. We considered respondents to be aware
of coverage if they answered yes to this question.
Defining users of SCT benefit
We asked self-reported smokers if their health plan had
paid for prescription medications to help them quit smok-
ing. We posed a separate question for each of the four pre-
scription medications covered. In 2001, we asked respon-
dents to reply to these questions based on their experience
since January 1, 2001, the effective date of the SCT insur-
ance coverage. In 2002, we asked respondents to reply
based on their experience during the past 12 months.
Defining users of OTC medications
In 2002, we asked self-reported smokers if they had pur-
chased OTC medication, such as the nicotine patch or nico-
tine gum, to help them quit smoking. We defined OTC
users as those who reported they had made such a pur-
chase. An individual could potentially report the prescrip-
tion benefit use, OTC use, or both.
Data analysis
Analyses consisted of descriptive statistics and tests of
the relationships between survey year and each outcome.
We used Stata version 8.0 (Stata Corp, College Station,
Tex) (20) to perform all analyses, which were weighted for
representativeness in the population. To test for differ-
ences in demographic characteristics between 2001 and
2002, we used a Pearson chi-square test for variables with
multiple response options (age and education) and a
Student  t test for sex. For smoking prevalence, benefit
awareness, benefit use, and OTC medication use, we esti-
mated population rates adjusted for the sampling weights.
For the outcomes assessed in both survey years using 
comparable survey questions — smoking prevalence and
benefit awareness — we used a Student t test to test for a
difference in population means between 2001 and 2002.
Results
Table 3 presents the demographic characteristics of the
unweighted sample data; Table 4 presents the demo-
graphic characteristics of the weighted sample data. We
discuss below the weighted sample demographics because
our aim is to make inferences to the state employee,
retiree, and adult dependent population as a whole. More
than 80% of the sample had some college education, and
more than 55% of the sample had a 4-year college degree
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year were male. Differences in age, education, and sex for
2001 and 2002 were not statistically significant. We
assume that the demographic characteristics of the sam-
ples reflect the state employee, retiree, and adult depend-
ent population for each year.
The study outcomes assessed in 2001 and 2002 are pre-
sented in Table 5. Population smoking prevalence esti-
mated from the sample declined from 15.6% in 2001 to
13.2% in 2002 (P = .01). Awareness of the benefit grew
from an initial 20.6% of smokers in 2001 to 27.4% in 2002
(P = .02). During the first 3 to 6 months of the benefit’s
availability in 2001, 7.1% of smokers reported benefit use.
In 2002, 13.6% reported benefit use. Benefit use among
smokers aware of the benefit was 23.6% in 2001 and 39.6%
in 2002. Benefit use among smokers who were unaware of
the benefit was 2.9% in 2001 and 3.5% in 2002. (Unaware
smokers who reported using the benefit would have paid a
typical copayment to receive SCT medications. We assume
that they did not interpret use of a copayment as insur-
ance coverage for SCT medications.)
In 2002, we also collected information on OTC medica-
tion use. These findings are presented in Table 6. We
found that 9.3% of smokers reported use of the benefit
alone (i.e., no OTC medication use). Use of OTC medica-
tions alone was reported by 16.9% of smokers (i.e., no ben-
efit use). Few smokers (4.2%) used both OTC medications
and the benefit. Of smokers unaware of the benefit, 21.4%
reported using OTC medications only to help them quit
smoking; 5.2% of smokers aware of the benefit reported
using OTC medications only. Among all smokers in 2002,
30.4% reported use of some medication to help them quit
smoking (i.e., OTC, benefit, or both).
Discussion
In a highly educated, working-age population, use of a
new SCT benefit was modest among all smokers during
its first 2 years of availability. In its second year of
availability, only 13.6% of all smokers used the benefit
to help quit smoking. However, among smokers who
were aware of the benefit, the benefit use rate was high-
er at 39.6%. These findings are relevant to employers
and purchasers in need of population-based benefit-use
estimates to introduce their own SCT benefit. For
example, 25 state-government employers do not provide
an insurance benefit for SCTs to some or all of their
employees (9).
There are several potential explanations for the modest
benefit-use rates for all smokers identified in this study.
Low benefit awareness is one possibility. As described
above, the state’s promotion of the new benefit was limit-
ed. In our study, we found greater benefit use among
smokers who were aware of the benefit and greater use of
only OTC medications among smokers who were unaware
of the benefit. In 2002, 39.6% of smokers aware of the ben-
efit and 3.5% of smokers unaware of the benefit reported
using the benefit. In that same year, 21.4% of smokers
unaware of the benefit and 5.2% of smokers aware of the
benefit reported using OTC medications only to help them
quit smoking. Boyle et al also found that smokers aware of
the benefit were more likely to use Zyban, one of the cov-
ered medications in that study, to make an attempt to quit
than smokers who were unaware of the benefit (15). To our
knowledge, only one study has examined the effect of a
benefit-promotion intervention on smokers’ knowledge
and use of a SCT benefit. In a randomized controlled trial,
Alesci et al found greater benefit knowledge among smok-
ers who received a promotional postcard than those who
received notification of the new SCT benefit within annu-
al health plan enrollment materials (21). There was no dif-
ference, however, in benefit-use rates between the two
groups. Additional research is needed to identify commu-
nication strategies that increase benefit awareness and
use to inform employers’ implementation and promotion of
SCT coverage.
Alternatively, perhaps low smoker interest in quitting
explains the relatively low rate of benefit use we observed.
This explanation, however, seems unlikely. Nationally,
70% of current smokers report that they want to quit smok-
ing (22), and approximately 41% of daily smokers reported
making an attempt to quit at least 1 day during the past 12
months (23). In our study, the overall annual SCT use rate
(benefit or OTC use) was roughly 30%. This rate implies
greater quitting activity than suggested by our annual ben-
efit-use rate of roughly 14%. Future research that exam-
ines benefit features such as the products and services cov-
ered, their limitations, and how a patient gains access to a
benefit may further explain the factors that influence ben-
efit-use rates. Additionally, research that explores smokers’
reasons for not using an available SCT benefit would be
useful in understanding factors that may increase demand
and inform benefit design.
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As noted above, annual medication use for SCT in the
Wisconsin state employee population, obtained through
the insurance benefit or OTC, was roughly 30% of all
smokers in 2002. This rate of treatment use is high com-
pared with population-based rates found elsewhere. For
example, in 1996, just 20% of smokers who attempted to
quit smoking used some form of assistance, self-help, coun-
seling, nicotine replacement therapy, or a combination of
these (24). Since that time, the variety and availability of
FDA-approved medications for smoking cessation has
increased. Results from a 2000 survey found that approxi-
mately 25% of privately insured smokers who attempted
to quit smoking used a cessation aid (25). The FDA-
approved medications assessed in our study can double or
triple the likelihood of achieving abstinence from smoking
compared with quitting without a cessation aid (3). Our
population’s rate of SCT use may suggest that smokers are
increasingly using these efficacious cessation aides.
Based on our rate of OTC medication use, some may con-
clude that an SCT benefit is unnecessary or redundant.
However, if the objective is to maximize smokers’ opportu-
nities to quit, the presence of an SCT benefit may help do
just that. It may increase the number of smokers who
make an attempt to quit. From our data, we could not
determine whether the use of this new benefit may have
supplanted the use of OTC medications. Future research
should examine the extent to which an SCT benefit
increases the number of smokers who make an attempt to
quit beyond those who use OTC medications, the number
of attempts to quit made beyond those made with the
assistance of OTC medications, and the outcomes of those
attempts to quit.
Ultimately, the likely value of insurance coverage for
SCTs to insurers, employers, and purchasers is its effect
on smoking prevalence. Studies have demonstrated a
promising link between SCT coverage and improved quit
rates (5) and reduced smoking prevalence (4). We observed
a significant decline in smoking prevalence in the study
population during the first 2 years of the benefit’s avail-
ability, from approximately 15% to 13%. Low smoking
rates are typical among highly educated populations
nationally (23) and in Wisconsin (26); thus, the level that
we observed is not in itself surprising. However, the
decline in smoking prevalence during this short period
suggests the need for further research to identify its caus-
es. Caution should be used in linking this decline in preva-
lence solely to the new SCT benefit as other factors may
apply. Our study design did not allow us to isolate the
effect of the new SCT benefit on smoking prevalence in the
population.
This study has a number of limitations. The sample
design was a random sample of employee and retiree con-
tracts for health insurance stratified by plan. The stratifi-
cation did not extend to the level of sex, age, or education
within each plan. Some of these variables have been asso-
ciated with smoking status (23) and OTC use (27). To the
extent that the sampling design did not capture a repre-
sentative sample of the population, our population out-
come estimates for prevalence of smoking and OTC use
may be somewhat biased. We are not aware of any pub-
lished evidence demonstrating an association between sex,
age, and educational level with benefit use and benefit
awareness.
We made two changes to the survey between 2001 and
2002. First, we altered the reporting period for benefit use.
In 2001, we asked respondents to report on benefit use
during the first 3 to 6 months of the benefit’s availability,
beginning with January 1, 2001. In 2002, we asked them
to report on benefit use during the previous 12 months.
Thus, the 2001 survey reflected 3 to 6 months of SCT cov-
erage, and the 2002 survey reflected 12 months of SCT
coverage. Because the benefit-use rates reflect different
time periods, they should not be directly compared.
Second, we added a question to assess OTC use in 2002.
The survey respondent was the person in the household
most knowledgeable about the health care received by all
family members covered by the plan. To the extent that
such a knowledgeable person is more likely to be aware of
and use the SCT benefit, our estimated benefit awareness
and use rates may overstate what employers will observe
in their insured populations. Future research using claims
data to assess benefit use would help to address this poten-
tial limitation.
Our study results can help employers overcome a com-
mon barrier to the introduction of insurance coverage for
SCTs: uncertainty about levels of employee use of a new
SCT benefit. We found that approximately 14% of all
smokers used the benefit to help quit smoking during its
second year of availability. This benefit-use rate provides
employers with essential information to estimate the cost
of a new SCT benefit. By providing this decision-relevant
information to employers, our results may hasten the
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erage for SCTs (1-3). In addition to serving employers’
informational needs, these findings may inform public pol-
icy more generally as state and federal governments con-
sider implementing the National Action Plan for Tobacco
Cessation’s recommendation to provide universal coverage
for evidence-based SCT medications (28).
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Tables
Table 1. Wisconsin State Employees’ Insurance Benefit for Smoking-Cessation Treatment, Effective January 1, 2001a
aSource is the Wisconsin Department of Employee Trust Funds (17).
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Component Cost to Employee Limits
Coverage includes pharmacological products that by law require a written
prescription and are prescribed by a plan provider for the purpose of
achieving smoking cessation (i.e., Zyban, nicotine inhaler, spray or patch)
Coverage includes one office visit for counseling and to obtain the pre-
scription
Subject to standard prescription
drug co-payment and out-of-
pocket maximum
None
One 3-month course per
year
One office visit per yearTable 2. Sample Strata, Wisconsin Consumer Assessment of Health Plans Survey 2001 and 2002
1 9,897 21,773 353 9,489 20,876 368
2 8,131 17,888 367 NAa NA NA
3 16,381 36,038 382 14,948 32,886 377
4 3,876 8,527 339 NA NA NA
5 1,138 2,503 287 1,075 2,365 294
6 8,125 17,875 367 7,551 16,612 368
7 1,966 4,325 321 1,869 4,112 325
8 754 1,658 254 721 1,586 274
9 423 930 176 419 922 234
10 1,351 2,972 299 571 1,256 237
11 803 1,766 260 772 1,698 267
12 503 1,106 217 450 990 221
13 408 898 148 379 834 217
14 2,860 6,292 339 2,667 5,867 339
15 3,456 7,603 346 3,057 6,725 345
16 2,547 5,603 334 1,554 3,419 323
17 10,028 22,061 370 8,894 19,567 370
18 7,340 16,148 365 5,943 13,075 365
19 2,997 6,593 341 2,934 6,455 348
20 NA NA NA 1,315 2,893 327
21 NA NA NA 567 1,247 274
22 NA NA NA 631 1,388 290
23 NA NA NA 2,935 6,457 367
24 NA NA NA 919 2,012 283
Total 82,984 182,559 5,865 69,660 153,242 6,813
aNA indicates that this health plan did not serve the state employee and retiree population in the year listed.
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2001 Sample Strata 2002 Sample Strata
No. Contracts in Estimated No. No.  No. Contracts in  Estimated No.  No. 
Health Plan Sampling Frame State Members Respondents Sampling Frame State Members RespondentsVOLUME 2: NO. 4
OCTOBER 2005
Table 3. Unweighted Sample Characteristics, Wisconsin State Employees, Retirees, and Adult Dependents, Wisconsin
Consumer Assessment of Health Plans Survey 2001 and 2002
Age, y
18-24 144 (2.5) 133 (2.1)
25-44 2217 (40.0) 2407 (37.1)
45-64 2617 (46.7) 3211 (49.5)
>65 611 (10.8) 733 (11.3)
Totala 5589 (100.0) 6484 (100.0)
Education
<High school graduate 95 (1.8) 91 (1.4)
High school graduate or GED 965 (17.2) 1129 (17.4)
Some college 1340 (23.9) 1530 (23.6)
4-year college degree or more 3199 (57.1) 3733 (10.0)
Totala 5599 (100.0) 6483 (100.0)
Sex
Male 2589 (46.2) 2986 (45.8)
Female 3020 (53.8) 3532 (54.2)
Total 5609 (100.0) 6518 (100.0)
aBecause of missing data, the total number of respondents to this question does not equal the total number of respondents in the analytic sample (i.e.,
5609 in 2001 and 6518 in 2002).
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Unweighted Sample
2001 2002 
(N = 5609) (N = 6518)
No. (%) No. (%)Table 4. Weighted Sample Characteristics, Wisconsin State Employees, Retirees, and Adult Dependents, Wisconsin Consumer
Assessment of Health Plans Survey 2001 and 2002a
Age, y
18-24 3.0 2.7 .20
25-44 40.9 38.7
45-64 46.6 48.6
>65 9.5 10.0
Education
<High school graduate 1.6 1.3 .51
High school graduate or GED 15.9 15.9
Some college 22.1 23.5
4-year college degree or more 60.3 59.2
Sex
Male 44.1 43.9 .86
aThe sample data were weighted to be representative of the insured State of Wisconsin employee, retiree, and adult dependent population. 
bPearson’s chi-square test was used to test differences from 2001 to 2002 within the age and education categories; a Student t test was used to test for
differences in the sex category.
Table 5. Smoking Prevalence, Awareness of Benefit, and Use of Benefit Among Wisconsin State Employees, Retirees, and
Adult Dependents, Wisconsin Consumer Assessment of Health Plans Survey 2001 and 2002
Smoking prevalence 15.6 (14.3-16.8) 13.2 (12.0-14.4) .01
Awareness of insurance benefit for smoking 20.6 (17.0-24.2) 27.4 (23.1-31.7) .02
Use of insurance benefit
Among all smokers 7.1 (4.7-9.5) 13.6 (10.2-16.9) c
Among smokers aware of benefit 23.6 (15.2-32.1) 39.6 (30.3-48.7) c
Among smokers unaware of benefit 2.9 (0.9-4.9) 3.5 (1.2-5.7) c
aCI indicates confidence interval.
bThe change in mean percentage from 2001 to 2002 was analyzed using a Student t test. 
cBenefit use rates are not directly comparable. The 2001 survey was conducted between March and June 2001. 2001 respondents reported on benefit use
“since January 1, 2001.” Respondents in 2002 reported on benefit use “during the past 12 months.”
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Weighted Sample, %
2001 2002 P valueb
Sample Population
2001 2002
% (95% CIa) % (95% CI) P valuebVOLUME 2: NO. 4
OCTOBER 2005
Table 6. Over-the-Counter (OTC) Medication and Benefit Use Among Wisconsin State Employees, Retirees, and Adult
Dependents Who Smoke, Wisconsin Consumer Assessment of Health Plans Survey 2002
Among all smokers
Benefit use only 9.3 (6.6-12.1)
OTC use only 16.9 (13.2-20.5)
Benefit use and OTC use 4.2 (2.1-6.4)
Benefit use, OTC use, or both 30.4 (25.9-35.0)
Among smokers aware of benefit
OTC use only 5.2 (2.4-8.0)
Among smokers unaware of benefit
OTC use only 21.4 (16.7-26.2)
aCI indicates confidence interval.
12 Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2005/oct/05_0007.htm
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only
and does not imply endorsement by any of the groups named above.
Sample Population
% (95% CIa)